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INTRODUCTION
Although the Infectious Disease Society of 
America (IDSA) recommends measurement of 
renal function prior to initiation of antiretroviral 
therapy (ART) (1) and regular screening of renal 
chemistry while on ART, majority of the patients 
in resource constrained settings do not conform 
to these guidelines largely due to ﬁnancial 
constraints. Those that attempt to measure 
renal chemistries, use serum creatinine as an 
estimation of the renal function. However, serum 
creatinine alone is not ideal for the measurement 
of renal function. Many HIV positive patients 
present late in our set-up. At presentation, these 
patients usually have weight loss with signiﬁcant 
reduction in muscle mass. Serum creatinine 
is inﬂuenced by muscle mass even without a 
change in glomerular ﬁltration rate. The current 
recommendation is that the glomerular ﬁltration 
rate (GFR), rather than serum creatinine, be used 
to assess the degree of renal impairment and to 
follow the course of renal disease. 
Several modalities have been utilised in 
the general population to determine the GFR. A 
twenty four hour urine collection and subsequent 
measurement of creatinine clearance (CrCl) 
was once commonly used. However, attendant 
problems of accurate urine collection, timing, 
convenience and cost have relegated this method 
predominantly to in-patients where this can 
be supervised. It is now acceptable to estimate 
creatinine clearance using either Cockcroft 
Gault or the modiﬁcation of diet in renal disease 
(MDRD) formula (2,3). Based on this, most 
guidelines on ART recommend antiretroviral 
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ANTIRETROVIRAL THERAPY DOSE ADJUSTMENTS BASED ON  
CALCULATED CREATININE CLEARANCE
J. SHAVADIA, G. TESFALDET and M. TWAHIR
ABSTRACT
Background: Whereas therapy for HIV is dependent on level of creatinine clearance, most 
laboratories locally only report an absolute creatinine value. There is likelihood that the 
patients already on antiretroviral therapy (ART) may have required dosage adjustment at 
the time of initiation of therapy or sometime during ongoing therapy. This paper explores a 
group of patients who are already on ART to determine their creatinine clearance and assess 
the need for ART dose adjustment.
Objective: To determine the proportion of stable HIV outpatients who have a documented 
creatinine clearance (CrCI) and the proportion requiring antiretroviral drug dose adjustments 
depending on their creatinine clearance.
Design: Retrospective observational study.
Setting: One stop HIV medical clinic, Aga Khan University Hospital, Nairobi between 
January and February 2007.
Subjects: Ninety three patients seen.
Results: None of the study subjects had a calculated creatinine clearance in their medical 
records. Fifteen of the 93 patients (16.1%) had no serum creatinine performed in the twelve 
months preceding the last clinic visit. Nine of the remaining 78 patients (11.5%) had evidence 
of renal insufﬁciency (CrCI <60mls/min) as estimated by the Cockroft Gault method, with 
six patients (7.7%) requiring dose adjustments to the one or more drugs in their antiretroviral 
therapy (ART) regime (CrCI <50mls/min).
Conclusion: It is imperative to have a CrCI prior to and during follow up of patients with 
HIV disease on ART to reduce potential drug toxicities and interactions, especially with the 
increased utilisation of newer and potentially more nephrotoxic antiretrovirals.
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dose adjustment based on calculated GFR rather 
than serum creatinine levels (1-4).
Although highly active antiretroviral 
therapy (HAART) has revolutionised the 
treatment of HlV-infected patients, new problems 
have emerged, such as viral resistance, drug 
interactions and drug-related adverse effects. 
This has therefore made ARV drug prescription 
increasingly complex, predisposing to 
prescription errors, both in hospitalised patients 
and the out-patient setting (5-9). In a review of 
209 admissions over a one-year period, Rastegar 
et al (7) reported that in 16.7% of hospitalised 
HIV-infected patients, ARV medication errors 
were due to incorrect amount or frequency of 
dosage; over half of these errors were attributable 
to failure to appropriately adjust dosage for renal 
insufﬁciency.
Several antiretroviral medications may 
have renal adverse events. Conversely, many 
patients with already impaired renal function 
have increased incidence of side effects of ART 
such as neuropathy, lipodystrophy and Fanconi 
syndrome (1). There have been several case 
reports of renal failure in patients on teno fovir 
(10-14), most of whom had normal renal function 
prior to initiation of ART. This deterioration of 
renal function is potentially worse in patients who 
have an impaired baseline creatinine clearance. 
Wools-Kaloustian et al (15) performed a 
cross-sectional study in an ARV-naive Kenyan 
population and found baseline renal insufﬁciency 
deﬁned as a CrCI <60mls/min in 11.5% and CrCl 
<50mls/min in 4.8% of the study population. 
With an HIV prevalence rate of 7.8% (16) in 
the Kenyan population of 37 million, over two 
million would be HlV-infected of whom, close to 
300,000 HIV infected patients may have potential 
baseline renal insufﬁciency. When these patients 
are commenced on HAART, close monitoring of 
their renal function would be required, both prior 
to and during therapy. 
Whereas therapy of HIV is dependent 
on level of creatinine clearance, most of the 
laboratories in our country only report creatinine 
as an absolute value. There is a likelihood that 
the patients already on ART may have required 
dosage adjustment at the time of initiation of 
therapy or sometime during ongoing therapy. 
This paper explores this group of patients 
who are already on ART and determine their 
creatinine clearance thereby determining those 
whose treatment should have been adjusted. 
MATERIALS AND METHODS
One hundred and twenty seven patient records 
which met criteria for inclusion and excluded 
thirty four who either were not on ART or had 
insufﬁcient data on their age, gender and weight. 
Analysis was therefore performed for ninety-three 
patients’ records between January and February 
2007. Since these patients re-attended the out-
patient clinic after February 2007, the last date 
of appointment in the year 2007 was noted and 
the following parameters obtained: Age, gender 
and race; weight at the last appointment date; 
outpatient serum creatinine in the preceding 12 
months of the last review date. We only utilised 
serum creatinine done as an out-patient since this 
parameter may change when patients are acutely 
unwell; ART regime and dosing as per the last 
review date; last available CD (4) count and 
plasma viral load within the preceding l2mo. 
Every eligible patient had a serum 
creatinine clearance calculated using both the 
Cockcroft-Gault and simpliﬁed MDRD method. 
Dosing recommendations was utilised as per the 
guidelines for the use of antiretroviral agents in 
HIV -infected adults and adolescents (15). 
RESULTS
The mean age was 42.8 years (25 - 67 years) and 
males comprised 61.3% of the study population 
giving a male: female ratio of 1.6: 1. All our 
patients were black Africans. 
Figure 1
ART use was distributed as follows 
    
TDF = Tenofovir FTC = Emtricitabine       
AZT = Zidovudine 3TC = Lamivudine       
d4T = Stavudine EFV = Efavirenz       
ABC = Abacavir NVP = Nevirapine       
ddI = Didanosine LPV /r = Lopinavir/ 
 Ritonavir 
Seventy eight point two per cent of patients had 
CD4 counts > 200 with the mean CD4 count of 385 
cells/mm3 (2-l304 cells/mm3). On analysis of the 
plasma viral load data available for 85 (91.4%) 
patients, 63 (74.1%) patients had undetectable 
viral loads (<50 copies/ml). 
None of the study patients either had 
a calculated creatinine clearance recorded in 
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their medical records or had had ART dosages 
adjusted. Fifteen of the 93 patients evaluated 
(16.1%) had not had a serum creatinine done 
in the 12 months preceding the last clinic visit. 
Of the 78 patients who had data on their serum 
creatinine, nine (11.5%) had a CrCl <60mls/min 
and six (7.7%) had a CrCI <50mIs/min as per the 
Cockroft Gault method while 7.6% and 3.8% had 
CrCI <60mls/min and <50mls/min respectively, 
as per the simpliﬁed MDRD formula. 
DISCUSSION
None of the study patients had a documented 
calculated creatinine clearance on which their 
ART dosing was based on. This is not in keeping 
with the recommendations either from the 
guidelines for the use of antiretroviral agents 
in HIV-infected adults and adolescents (l7) 
or the IDSA guidelines (1) which recommend 
ART dosing based on the CrCI. It is also not in 
tandem with the WHO guidelines (l8) for ARV 
monitoring in regional referral centres where 
full serum chemistries have been advocated as 
opposed to resource-limited settings at primary 
health care and district levels. 
From our study cohort, we also found 
7.7% of the patients had a CrCI <50mls/min, 
reﬂecting the proportion of patients who require 
dose adjustment in their ART, mainly in the 
nucleoside and nucleotide reverse transcriptase 
inhibitor dosing. Although not our primary 
aim, it would have been interesting to identify 
the proportion and nature of adverse events in 
this cohort of patients who actually had renal 
insufﬁciency and required ART dose adjustment. 
The predominant agents requiring dose 
modiﬁcation from our study included: tenofovir, 
emtricitabine, stavudine and lamivudine. An 
additional 3.8% of the study patients had a 
CrCI between 51-60mls/min and will therefore 
require close monitoring of their renal function. 
The need for dose adjustment of ART in patients 
with chronic kidney disease is under-appreciated 
by physicians offering care to patients with HIV 
disease. 
Over 60% of the patients in our study 
were on a tenofovir based ARV regime. However, 
the guidelines for antiretroviral therapy in Kenya 
(19) recommend the use of either stavudine or 
zidovudine as the nucleoside backbone. The 
difference is likely to be due to the simplicity of 
use and safety proﬁle of tenofovir, hence physician 
and patient preferences in using this drug. 
With increasing use of potentially 
nephrotoxic antiretrovirals, this calls for 
physicians taking care of patients with HIV 
disease to be vigilant in monitoring renal function 
and calculate the CrCI both prior and during 
treatment. It also adds to the growing momentum 
that CrCI rather than absolute creatinine values 
be reported by all laboratories to facilitate 
drug dosing and reduce toxicity proﬁles due to 
inadvertent drug overdosing. 
The IDSA guideline recommends use of 
the Cockroft-Gault formula for calculation of the 
CrCI to base drug dosing on. In our study, the 
Cockroft-Gault formula was able to identify twice 
as many patients with an estimated CrCI <50mls/
min, compared to the modiﬁed MDRD method. 
Due to this superiority and the ease of calculation 
of the CrCI using the Cockroft-Gault equation, 
this should probably be the recommended 
method in our population. However, this formula 
has neither been validated in our population nor 
in patients with HIV disease. Therefore, more 
local and regional data comparing the calculated 
methods of creatinine clearance to urinary 
clearance of exogenous ﬁltration markers is 
required in patients with HIV disease. 
Although not a primary goal of our 
study, we also noted that none of our patients had 
routine urinalysis done to test for proteinuria. 
Proteinuria is one of the presentations of HIV 
related kidney disease. This would have provided 
further supporting evidence to identify patients 
with kidney injury. 
In keeping with our study, available local 
and regional evidence suggest that approximately 
11.5% of ARV-naive HIV infected patients have 
baseline renal insufﬁciency (CrCI <60mls/min) 
(15). However, our study demonstrated a higher 
proportion of patients 7.7% versus 4.8% (5) with 
hitherto undetected signiﬁcant renal dysfunction 
of CrCI <50ml/min requiring dosage adjustment 
of the ARV prescription. This implies these 
patients are exposed to higher drug toxicity and 
nephrotoxic effects of the medication. 
In conclusion, the results of this study provides 
regional evidence, in addition to other loco-
regional studies (12), on the estimates of HIV 
infected patients requiring adjustments to their 
ARV regime based on their CrCI. It also cautions 
all treating physicians to calculate an estimated 
GFR both prior to, and after initiation of ART 
to ensure appropriate antiretroviral dosage 
and hence prevent attendant ARV toxicity. 
In addition, it calls for laboratories to report 
CrCI using the Cockroft Gault method rather 
than absolute creatinine values to facilitate 
improvement in care for patients with HIV 
disease. 
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